<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Comorbidities that affect management of rheumatoid arthritis in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Comorbidities that affect management of rheumatoid arthritis in adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Comorbidities that affect management of rheumatoid arthritis in adults</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Comorbid conditions</td> <td class="subtitle1">Pretreatment testing</td> <td class="subtitle1">Relevant drugs/monitoring</td> <td class="subtitle1">Notes</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Infections</td> </tr> <tr> <td class="indent1">Serious infections</td> <td> </td> <td> <ul> <li>Hold immunosuppressive medications</li> </ul> </td> <td> <ul> <li>Risk/benefit should be based on clinical judgment</li> </ul> </td> </tr> <tr> <td class="indent1">Hepatitis B past infection with natural immunity</td> <td> <ul> <li>HBcAb positive</li> <li>HBsAb positive</li> <li>HBsAg negative</li> <li>LFTs</li> </ul> </td> <td> <ul> <li>No change in recommended treatment, except for rituximab</li> </ul> </td> <td> <ul> <li>Monitor HBV viral load every 6 to 12 months</li> <li>Prophylactic antiviral therapy recommended with the use of rituximab</li> </ul> </td> </tr> <tr> <td class="indent1">Hepatitis B current/chronic infection</td> <td> <ul> <li>HBcAb positive</li> <li>HBsAb negative</li> <li>HBsAg positive</li> <li>HBeAg positive</li> <li>LFTs</li> </ul> </td> <td> <ul> <li>Consult with hepatologist prior to treatment</li> </ul> </td> <td> </td> </tr> <tr> <td class="indent1">Hepatitis C infection</td> <td> <ul> <li>HCV Ab or RNA</li> <li>LFTs</li> </ul> </td> <td> <ul> <li>Attempt to use non-hepatotoxic DMARDs initially</li> </ul> </td> <td> <ul> <li>Manage in collaboration with hepatologist</li> </ul> </td> </tr> <tr> <td class="indent1">Tuberculosis</td> <td> <ul> <li>PPD or interferon gamma release assay</li> </ul> </td> <td> <ul> <li>All patients prior to a bDMARD or tsDMARD (eg, JAK inhibitors) and those at risk prior to cDMARD therapy</li> </ul> </td> <td> <ul> <li>If positive, treat for latent tuberculosis, starting at least 1 month prior to starting immunomodulatory therapy</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Malignancy</td> </tr> <tr> <td class="indent1">Nonmelanoma skin cancer</td> <td> <ul> <li>Skin check</li> </ul> </td> <td> <ul> <li>All immunomodulatory agents</li> </ul> </td> <td> <ul> <li>Routine skin cancer surveillance</li> </ul> </td> </tr> <tr> <td class="indent1">Melanoma skin cancer</td> <td> <ul> <li>Skin check</li> </ul> </td> <td> <ul> <li>cDMARDs preferred over bDMARDs or tsDMARDs; generally avoid abatacept and TNF inhibitors; prefer rituximab if bDMARD needed</li> </ul> </td> <td> <ul> <li>Dermatology suggested follow-up surveillance per melanoma stage protocols</li> </ul> </td> </tr> <tr> <td class="indent1">Lymphoproliferative disorder</td> <td> </td> <td> <ul> <li>cDMARDs preferred over bDMARDs or tsDMARD; prefer rituximab if bDMARD needed</li> </ul> </td> <td> <ul> <li>Manage in consultation with hematology and oncology</li> </ul> </td> </tr> <tr> <td class="indent1">Solid organ malignancy</td> <td> </td> <td> <ul> <li>If &lt;5 years out, prefer cDMARDs over bDMARDs or tsDMARD; if &gt;5 years out, no change in treatment</li> </ul> </td> <td> <ul> <li>Manage in consultation with oncologist</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Cardiovascular disease</td> </tr> <tr> <td class="indent1">Congestive heart failure</td> <td> <ul> <li>Recent echocardiogram</li> </ul> </td> <td> <ul> <li>Caution with NSAIDs, GCs</li> <li>TNF inhibitors may worsen moderate to severe congestive heart failure and should be avoided</li> </ul> </td> <td> </td> </tr> <tr> <td class="indent1">Hypertension</td> <td> <ul> <li>BP monitoring</li> </ul> </td> <td> <ul> <li>LEF may raise BP</li> </ul> </td> <td> <ul> <li>Regular BP monitoring</li> </ul> </td> </tr> <tr> <td class="indent1">Hyperlipidemia</td> <td> <ul> <li>Lipid panel</li> </ul> </td> <td> <ul> <li>IL-6 inhibitors and tsDMARDs may increase lipids</li> </ul> </td> <td> <ul> <li>Lipid panel</li> <li>IL-6: every 6 months</li> <li>tsDMARD: 6 to 8 weeks after drug start</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Other</td> </tr> <tr> <td class="indent1">Lung disease</td> <td> <ul> <li>Chest radiograph and PFTs</li> </ul> </td> <td> <ul> <li>Caution with agents that may exacerbate lung issues: MTX, LEF, abatacept, rituximab, gold, SSZ, TNF inhibitor</li> </ul> </td> <td> <ul> <li>Avoid MTX in patients with significant or progressive ILD; bDMARDs may exacerbate COPD</li> </ul> </td> </tr> <tr> <td class="indent1">Demyelinating disorders</td> <td> </td> <td> <ul> <li>Avoid TNF inhibitors</li> </ul> </td> <td> </td> </tr> <tr> <td class="indent1">Diabetes</td> <td> <ul> <li>Blood glucose</li> <li>Hemoglobin A1C</li> </ul> </td> <td> <ul> <li>GCs may worsen</li> <li>HCQ and SSZ may lower blood glucose</li> </ul> </td> <td> <ul> <li>Caution patients on oral glucose-lowering agents to watch for hypoglycemia</li> </ul> </td> </tr> <tr> <td class="indent1">Kidney disease</td> <td> <ul> <li>sCr, GFR</li> </ul> </td> <td> <ul> <li>Dose medications for GFR</li> <li>For severe kidney disease, avoid MTX, CSA</li> </ul> </td> <td> <ul> <li>Serial sCr and GFR</li> </ul> </td> </tr> <tr> <td class="indent1">Gastrointestinal disease</td> <td> <ul> <li>History of diverticulitis</li> </ul> </td> <td> <ul> <li>Avoid IL-6 inhibitors and tsDMARDs, which may increase risk of diverticular and other gastrointestinal perforation</li> </ul> </td> <td> <ul> <li>Higher risk with concomitant NSAIDs or GCs</li> </ul> </td> </tr> <tr> <td class="indent1">Pregnancy</td> <td> </td> <td> <ul> <li>Avoid MTX, LEF</li> </ul> </td> <td> <ul> <li>RA frequently remits during pregnancy</li> <li>Manage in consultation with OB-GYN</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">These are general guidelines. Patients should be assessed on an individual basis to determine if they require additions or other modifications to the monitoring and other guidance noted in this table. Refer to the UpToDate topic review on the general principles and overview of management of rheumatoid arthritis in adults.</div><div class="graphic_footnotes">bDMARD: biologic DMARD; BP: blood pressure; COPD: chronic obstructive pulmonary disease; cDMARD: conventional DMARD; CSA: cyclosporin A; DMARDs: disease-modifying antirheumatic drugs; GCs: glucocorticoids; GFR: glomerular filtration rate; HBcAb: hepatitis B core antibody; HBeAg: hepatitis B e-antigen; HBsAb: hepatitis B surface antibody; HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus; HCQ: hydroxychloroquine; HCV Ab: hepatitis C virus antibody; IL-6: interleukin 6; ILD: interstitial lung disease; JAK: Janus kinase; LEF: leflunomide; LFTs: liver function tests; MTX: methotrexate; NSAIDs: nonsteroidal antiinflammatory drugs; PFTs: pulmonary function tests; PPD: purified protein derivative; RA: rheumatoid arthritis; sCr: serum creatinine; SSZ: sulfasalazine; TNF: tumor necrosis factor.</div><div id="graphicVersion">Graphic 129740 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
